Paper Details

  1. Home
  2. Paper Details

Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.

Author: BartolomeSonja, BattarjeeWejdan F, BurgerCharles D, ChakinalaMurali M, FordHubert J, Gomberg-MaitlandMardi, HillNicholas S, KrowkaMichael, PrestonIoana R, SafdarZeenat, SoodNamita

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study is evaluating the efficacy and safety of ambrisentan, a drug used for Group 1 pulmonary arterial hypertension (PAH), in treating portopulmonary hypertension (PoPH), a subset of Group 1 PAH.
Paper Details　
Original Abstract of the Article :
Ambrisentan has shown effectiveness in the treatment of Group 1 pulmonary arterial hypertension (PAH). Although portopulmonary hypertension (PoPH) is a subset of Group 1 PAH, few clinical trials have been testing PAH therapies in patients with PoPH. The objective of this study is to evaluate the eff...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.healun.2019.12.008

データ提供：米国国立医学図書館（NLM）

Ambrisentan for Portopulmonary Hypertension: A New Hope

The study focuses on the efficacy and safety of ambrisentan, a drug already proven effective for treating Group 1 pulmonary arterial hypertension (PAH), in treating portopulmonary hypertension (PoPH), a subset of Group 1 PAH. This research seeks to address the limited number of clinical trials investigating PAH therapies in patients with PoPH. The study aims to assess the effectiveness and safety of ambrisentan in treating PoPH, offering hope for patients with this challenging condition.

Expanding Treatment Options for Portopulmonary Hypertension

This study holds significant promise for expanding treatment options for patients with PoPH. By investigating the effectiveness of ambrisentan in this specific patient population, the research could pave the way for more targeted and effective therapies for PoPH. This research is a step forward in our understanding of PoPH and its treatment.

A New Horizon in PoPH Treatment

The findings of this study could lead to improved therapeutic strategies for PoPH, offering hope for patients who are currently navigating a limited treatment landscape. This research is a testament to the ongoing search for innovative therapies to address complex and often debilitating conditions like PoPH.

Dr.Camel's Conclusion

The search for effective therapies for PoPH is like a quest through a vast and unforgiving desert. This study is like a refreshing oasis, offering hope for patients with this challenging condition. The research's focus on ambrisentan, a promising medication, suggests a potential path to improved treatment options for individuals with PoPH.

Date :
  1. Date Completed 2021-01-20
  2. Date Revised 2021-01-20
Further Info :

Pubmed ID

32008947

DOI: Digital Object Identifier

10.1016/j.healun.2019.12.008

Related Literature

Article Analysis
・Effective treatment of pulmonary hypertension
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.